Use of Monoclonal Antibody to Treat COVID-19 in Children and Adolescents: Risk of Abuse of Prescription and Exacerbation of Health Inequalities

Monoclonal antibodies (mAbs) that neutralize SARS-CoV-2 in infected patients are a new class of antiviral agents approved as a type of passive immunotherapy. They should be administered to adults and children (≥12 years old, weighing ≥ 40 kg) with SARS-CoV-2 positivity, and who are suffering from a...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito, Susanna, Zona, Stefano, Pession, Andrea, Iughetti, Lorenzo, Migliori, Giovanni Battista, Principi, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308584/
https://www.ncbi.nlm.nih.gov/pubmed/34358099
http://dx.doi.org/10.3390/ph14070673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308584/
https://www.ncbi.nlm.nih.gov/pubmed/34358099
http://dx.doi.org/10.3390/ph14070673

Ejemplares similares